ClinicalTrials.gg
CompletedNCT05492318Updated Jan 6, 2025Results posted

Perpetrator DDI Potential of Givinostat as Inhibitor and Inducer of CYP3A and P-gp Activity

A Phase 1 interventional study of Givinostat 10 mg/mL and Midazolam 1mg/ml IV in Drug-Drug Interaction and Heathy Volunteer, sponsored by Italfarmaco. Completed at 1 site in Portugal. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-06.

Sponsored by Italfarmaco · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Primary objective:

  1. To assess the potential inhibitory and inducing effect of oral givinostat on the single dose pharmacokinetics (PK) of intravenous or oral midazolam.
  2. To assess the potential inhibitory and inducing effect of oral givinostat on the single dose PK of oral dabigatran etexilate.

Secondary objective:

To assess the safety and tolerability of concomitant administration of givinostat plus midazolam and dabigatran etexilate.

Read the detailed description

This study was planned as a phase I, open-label, 3-part, fixed-sequence, nonrandomized study in healthy male and female subjects. The study evaluated the givinostat (ITF2357) potential drug-drug interaction (DDI) at level of CYP3A-mediated metabolism and P-glycoprotein (P-gp) transport with intravenous or oral midazolam and with oral dabigatran etexilate.

More precisely, the study aimed at assessing the potential (inhibitory or inducing) effect of givinostat on the PK of midazolam IV, on the PK of oral midazolam and on the PK of dabigatran etexilate.

The study lasted from Day 1 to Day 20. Subjects were confined from Day -1 to Day 20. On Days 6 and 17, single doses of 1 mg midazolam IV and 75 mg dabigatran etexilate, were administered 1 hour after the planned morning time of givinostat administration. On day 1, however, drugs were not administered 1h after gininostat.

On Days 7 and 18, a single oral dose of 2.5 mg midazolam oral solution was administered 1 hour after the planned morning time of givinostat administration.

On day 2, however, the drugs were not administered 1h after gininostat.

From Day 4 to Day 18, givinostat 50 mg as oral suspension was administered twice a day, in the morning and in the evening.

On Day 19, only the morning dose was administered.

The following assessments were performed:

  • Blood collection for pharmacokinetic analysis on Days 1 to 4, 6 to 9 and 17 to 20.
  • Vital signs measurements (BP, PR and RR) on Days 1, 2, and 4 to 19.
  • 12-lead ECG on Days 3 to 19.
  • Blood collection for laboratory tests (hematology, biochemistry and coagulation on Days 4 and 9 and hematology on Days 6, 12, 15 and 18). Subjects were discharged from BlueClinical Phase I in the morning of Day 20 if allowed by the investigator based on their medical condition. The following procedures were performed:
  • Physical examination.
  • Collection of body weight.
  • Vital signs measurements (BP, PR, RR and body temperature).
  • 12-lead ECG.
  • Safety laboratory assessments (hematology, biochemistry, coagulation and urinalysis).
  • Serum pregnancy test for all female subjects. Subjects returned to the site 10 to 14 days after the end of study to undergo additional assessments as required per protocol.

The total duration of Part 1 for each subject was up to approximately 8 weeks from Screening to Follow-up visit, divided as follows:

  • Screening: up to 21 days
  • Treatment Period: Days 1 to 20
  • Safety follow-up visit: 12±2 days
02

Conditions studied

  • Drug-Drug Interaction
  • Heathy Volunteer

Keywords

  • PK
  • Pharmacokinetics
  • Givinostat
  • Midazolam
  • Dabigatran
03

In context

Lead sponsor

Italfarmaco is the lead sponsor of 35 studies on the registry; 5 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion criteria

A subject was considered eligible for the study if he/she fulfilled all the inclusion criteria:

  1. Subject's written obtained prior to any study-related procedure.
  2. Male or female subject, ≥18 and ≤55 years of age, at the time of signing the informed consent.
  3. (BMI) of 18.5 to 32.0 kg/m2 inclusive, and body weight ≥55 kg and ≤100 kg for females and body weight ≥60 kg and ≤110 kg for males.
  4. Non-smoker or ex-smoker (i.e. someone who abstained from using tobaccoor nicotine-containing products for at least 3 months prior to Screening).
  5. No diseases.
  6. No major surgery within 4 weeks prior to dosing.
  7. No clinically relevant abnormalities on physical examination.
  8. No clinically relevant abnormalities on 12-lead .
  9. No clinically relevant abnormalities on clinical laboratory tests.
  10. Negative test results for anti- 1 and 2 antibodies (anti-HIV-1Ab and anti-HIV-2Ab), surface antigen (HBsAg) and anti- virus antibodies (anti-HCVAb).
  11. Female subjects are eligible if they are of non- or agree to use a non-hormonal highly effective method from 28 days prior to Screening until at least 90 days after the last study drug administration. Nonchildbearing potential female is defined as:

    1. Menopausal, i.e. no menses for ≥ 12 months without an alternative medical cause other than menopause, and a high FSH level.
    2. Pre-menopausal female with documented hysterectomy, bilateral salpingectomy and/or bilateral oophorectomy.

    A non-hormonal effective contraceptive method is defined as:

    1. Intrauterine device.
    2. Bilateral tubal occlusion.
    3. Total abstinence of heterosexual intercourse, in accordance with the lifestyle of the subject.
    4. Vasectomized partner, who has received medical assessment of the surgical success, or clinically diagnosed infertile partner.
  12. Male subjects who are sexually active with a female partner of childbearing potential (pregnant or non-pregnant) must use contraception (condom) from product administration up to at least 90 days following the last study drug administration.
  13. Male subjects must ensure that his non-pregnant female partner of childbearing potential agrees to consistently and correctly use for the same period a highly effective method of contraception (see Section 8.5.3).
  14. Male subjects must be willing not to donate sperm until 90 days following the last study drug administration.
  15. Willingness and capability to comply with the requirements of the study and ability to understand the study procedures and the risks involved.

Exclusion Criteria

A subject was excluded from the study if he/she fulfilled any of the exclusion criteria:

At Screening

  1. Previous use of givinostat.
  2. History of anaphylaxis reaction or clinically significant drug reaction (e.g., angioedema, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis, drug-induced hypersensitivity syndrome, druginduced neutropenia).
  3. Known history of hypersensitivity and/or allergic reactions to givinostat, histone deacetylases (HDAC) inhibitors or to any in the formulation.
  4. History of sorbitol intolerance, sorbitol malabsorption or fructose intolerance.
  5. Any medical condition (e.g. gastrointestinal, renal or hepatic, including peptic ulcer, inflammatory bowel disease or pancreatitis) or surgical condition (e.g. cholecystectomy, gastrectomy) that may affect drug pharmacokinetics (absorption, distribution, metabolism or excretion) or subject safety.
  6. Systolic blood pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 60 or over 90 mmHg, or pulse rate lower than 50 or over 100 bpm.
  7. ˃450 msec.
  8. Subjects with history of cardiac arrhythmias (documented), family history of sudden cardiac death or history of additional risk factors for torsades-depointes (e.g. heart failure, hypokalemia, long QT syndrome).
  9. Having an estimated glomerular filtration () \< 90 mL/min, based on calculation by the Cockcroft-Gault formula and normalized to an average surface area of 1.73 m2.
  10. Any of the following abnormal laboratory test values:

    1. count below the lower limit of the normal range (LLN)
    2. Total white blood cells count below the LLN
    3. below the LLN
    4. Triglycerides above the (ULN)
    5. Potassium or magnesium below the LLN
  11. Positive urine alcohol, drugs-of-abuse or cotinine screen tests.
  12. Positive serum pregnancy test.
  13. If woman, she is breast-feeding.
  14. History of alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to the screening visit (i.e. more than 14 units of alcohol per week for males or more than 7 units for females).
  15. History of drug abuse within 1 year prior to screening or use of soft drugs (such as marijuana) within 3 months prior to the screening visit or hard drugs [such as cocaine, phencyclidine (PCP), crack, opioid derivatives including heroin, and amphetamine derivatives] within 1 year prior to screening.
  16. Participation in any clinical trial within the previous 2 months.
  17. Participation in more than 2 clinical trials within the previous 12 months.
  18. Blood donation or significant blood loss (≥ 450 mL) due to any reason or had plasmapheresis within the previous 2 months.
  19. Veins unsuitable for intravenous puncture on either arm.
  20. Difficulty in swallowing capsules, tablets or suspensions.
  21. Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study.

    Exclusion Criteria:

    At Admission to Treatment Period

  22. Any clinically relevant abnormalities on clinical laboratory tests.
  23. Positive urine alcohol, drugs-of-abuse or cotinine screen tests.
  24. Positive urine pregnancy test.
  25. Positive or inconclusive SARS-CoV-2 test prior to admission.
  26. Use of prescription or non-prescription medicinal products within the previous 28 days or within 5-half-lives of the medicinal product, whichever is longer.
  27. Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study.

    For Part 1 subjects:

    At Screening

  28. Known history of hypersensitivity and/or allergic reactions to midazolam, other benzodiazepines, dabigatran etexilate or to any excipient of the formulations.
  29. Clinically relevant history of impaired respiratory function, obstructive sleep apnea, myasthenia gravis, respiratory arrest and/or cardiac arrest.
  30. History of glaucoma.
  31. Presence of respiratory failure.
  32. Presence of active clinically significant bleeding.
  33. Lesion or condition considered to pose a significant risk factor for major bleeding including, but not limited to: current or recent gastrointestinal ulceration, malignant neoplasms, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial hemorrhage, known or suspected esophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities.
  34. Presence of a medical condition requiring anticoagulant treatment.

    At Admission to Treatment Period

  35. Treatment with anticoagulants within 28 days or 5 drug half-lives, whichever was longer, before admission.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Givinostat alone or combo with Midazolam IV and with oral Dabigatran, or combo with oral Midazolam

    On Days 1, 6 and 17, single doses of midazolam 1 mg IV and dabigatran etexilate 75 mg were administered 1 hour after the planned (as per Day 4) morning time of givinostat administration. On Days 2, 7 and 18, a single oral dose of midazolam 2.5 mg oral solution was administered 1 hour after the planned (as per Day 4) morning time of givinostat administration. From Day 4 to Day 18, givinostat 50 mg as oral suspension was administered twice a day, in the morning and in the evening. On Day 19, only the morning dose was administered.

    Drug: Givinostat 10 mg/mL · Drug: Midazolam 1mg/ml IV · Drug: Midazolam 2.5 mg oromucosal solution · Drug: Dabigatran etexilate 75 mg oral hard capsules

Interventions

  • DrugGivinostat 10 mg/mL

    Drug page: Givinostat

    10 mg/mL oral suspension. Givinostat 10 mg/ml oral suspension was administered once, in the morning, in Days 1, 2, 6, 7, 17 and 18), and twice a day (50 mg as oral suspension), in the morning and in the evening, from the Day 4 to Day 18. On Day 19, only the morning dose was administered.

    Also known as: ITF2357

  • DrugMidazolam 1mg/ml IV

    Drug page: Midazolam

    Midazolam 1 mg/ml, solution for intravenous administration. Midazolam 1mg/ml IV, single dose, was administered on Days 1, 6 and 17, 1 hour after the planned morning time of givinostat administration. Midazolam IV were administered with the subjects in a semi-recumbent position. Subjects remained semirecumbent until at least 3 hours post-dose.

    Also known as: Aurobindo®

  • DrugMidazolam 2.5 mg oromucosal solution

    Dose: 2.5 mg oromucosal solution. Midazolam 2.5 mg single oral solution was administered on Days 2, 7 and 18, 1 hour after the planned morning time of givinostat administration. Oral midazolam (and dabigatran etexilate) was administered following an overnight fasting of at least 8 hours and subjects remained fasted until at least 3 hours post-dose. Oral midazolam (and dabigatran etexilate) was administered with 150 mL of water. Except for water given with the investigational products, no fluids were allowed from 1 hour before midazolam and dabigatran dosing until 2 hours postdose. Water was provided ad libitum at all other times. Midazolam (and dabigatran etexilate) were administered with the subjects in a semi-recumbent position. Subjects remained semirecumbent until at least 3 hours post-dose.

    Also known as: Buccolam®

  • DrugDabigatran etexilate 75 mg oral hard capsules

    Dose: 75 mg; Dosage form: hard capsules On Days 1, 6 and 17, dabigatran etexilate 75 mg was administered (with midazolam 1mg IV) 1 hour after the planned morning time of givinostat administration. Dabigatran etexilate (and midazolam) was administered following an overnight fasting of at least 8 hours and subjects remained fasted until at least 3 hours post-dose Oral dabigatran etexilate (and oral midazolam) was administered with 150 mL of water. Except for water given with the investigational products, no fluids were allowed from 1 hour before dabigatran (and midazolam) dosing until 2 hours postdose. Water was provided ad libitum at all other times. Dabigatran etexilate (and Midazolam) was administered with the subjects in a semi-recumbent position. Subjects remained semirecumbent until at least 3 hours post-dose.

    Also known as: Pradaxa

06

What researchers measure

Primary outcomes

  1. Cmax for Midazolam, 1-hydroxymidazolam, Following Single Doses of the Parent Drug

    Maximum observed plasma concentration (Cmax) of midazolam and 1-hydroxymidazolam following Administration of Midazolam IV Alone (Day 1) and Co-Administration of Midazolam IV and Givinostat (Day 6 - Potential Inhibitory Effect, and Day 17 - Potential Inducing Effect) and following Administration of Oral Midazolam Alone (Day 2) and Co-Administration of Oral Midazolam and Givinostat (Day 7 - Potential Inhibitory Effect, and Day 18 - Potential Inducing Effect). 13 blood samples were collected at pre-dose and at 2 minutes, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12 and 24 hours after the administration of IV midazolam, on Days 1, 6 and 17, to determine midazolam and 1-hydroxymidazolam plasma concentrations. 11 blood samples were collected at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours after the administration of oral midazolam, on Days 2, 7 and 18, to determine midazolam and 1-hydroxymidazolam plasma concentrations.

    Time frame: In the turn of 24 hours after IV midazolam, single dose, administered at day 1,6,17 or after oral midazolam, single dose, administered at days 2, 7 and 18.

  2. Cmax for Dabigatran (Total and Free), Following Single Doses of the Parent Drug

    Maximum observed plasma concentration (Cmax) of total dabigatran and free dabigatran following Administration of Dabigatran Etexilate Alone (Day 1) and Co-Administration of Dabigatran Etexilate and Givinostat (Day 6 - Potential Inhibitory Effect, and Day 17 - Potential Inducing Effect). Fifteen (15) blood samples were collected in K2-EDTA collection tubes at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after the administration of dabigatran etexilate, on Days 1, 6 and 17, for the determination of total and free dabigatran plasma concentrations.

    Time frame: In the turn of 72 hours after administration of dabigatran on day 1,6,17

  3. Tmax for Midazolam, 1-hydroxymidazolam, Following Single Doses of the Parent Drug

    tmax =Time of occurrence of Cmax. 13 blood samples were collected at pre-dose and at 2 minutes, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12 and 24 hours after the administration of IV midazolam, on Days 1, 6 and 17, to determine midazolam and 1-hydroxymidazolam plasma concentrations. 11 blood samples were collected at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours after the administration of oral midazolam, on Days 2, 7 and 18, to determine midazolam and 1-hydroxymidazolam plasma concentrations.

    Time frame: In the turn of 24 hours after IV midazolam, single dose, administered at day 1,6,17 or after oral midazolam, single dose, administered at days 2, 7 and 18.

  4. Tmax for Dabigatran (Total and Free), Following Single Doses of the Parent Drug

    The time of occurrence of maximum observed concentration (tmax) of total dabigatran and free dabigatran following Administration of Dabigatran Etexilate Alone (Day 1) and Co-Administration of Dabigatran Etexilate and Givinostat (Day 6 - Potential Inhibitory Effect, and Day 17 - Potential Inducing Effect). Fifteen (15) blood samples were collected at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after the administration of dabigatran etexilate, on Days 1, 6 and 17, for the determination of total and free dabigatran plasma concentrations.

    Time frame: In the turn of 72 hours after administration of dabigatran on day 1,6,17

  5. t1/2 of Midazolam, 1-hydroxymidazolam, Following Single Doses of Givinostat

    T1/2 is the Apparent terminal elimination half-life, calculated as ln(2)/λz. t1/2 of midazolam and 1-hydroxymidazolam following Administration of Midazolam IV Alone (Day 1) and Co-Administration of Midazolam IV and Givinostat (Day 6 - Potential Inhibitory Effect, and Day 17 - Potential Inducing Effect) and following Administration of Oral Midazolam Alone (Day 2) and Co-Administration of Oral Midazolam and Givinostat (Day 7 - Potential Inhibitory Effect, and Day 18 - Potential Inducing Effect). 13 blood samples were collected at pre-dose and at 2 minutes, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12 and 24 hours after the administration of IV midazolam, on Days 1, 6 and 17, to determine midazolam and 1-hydroxymidazolam plasma concentrations. 11 blood samples were collected at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours after the administration of oral midazolam, on Days 2, 7 and 18, to determine midazolam and 1-hydroxymidazolam plasma concentrations.

    Time frame: In the turn of 24 hours after IV midazolam, single dose, administered at day 1,6,17 or after oral midazolam, single dose, administered at days 2, 7 and 18.

  6. t1/2 for Dabigatran (Total and Free), Following Single Doses of the Parent Drug

    Apparent terminal elimination half-life, calculated as ln(2)/λz. The t1/2 of total dabigatran and free dabigatran following Administration of Dabigatran Etexilate Alone (Day 1) and Co-Administration of Dabigatran Etexilate and Givinostat (Day 6 - Potential Inhibitory Effect, and Day 17 - Potential Inducing Effect). Fifteen (15) blood samples were collected at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after the administration of dabigatran etexilate, on Days 1, 6 and 17, for the determination of total and free dabigatran plasma concentrations.

    Time frame: In the turn of 72 hours after administration of dabigatran on day 1,6,17

  7. AUC0-t of Midazolam, 1-hydroxymidazolam, Following Single Doses of Givinostat

    AUC0-t =area under the curve from time zero to last sampling time with quantifiable concentrations. AUC0-t of midazolam and 1-hydroxymidazolam following Administration of Midazolam IV Alone (Day 1) and Co-Administration of Midazolam IV and Givinostat (Day 6 - Potential Inhibitory Effect, and Day 17 - Potential Inducing Effect) and following Oral Midazolam Alone (Day 2) and Co-Administration of Oral Midazolam and Givinostat (Day 7 - Potential Inhibitory Effect, and Day 18 - Potential Inducing Effect). 13 blood samples were collected at pre-dose and at 2 minutes, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12 and 24 hours after the administration of IV midazolam, on Days 1, 6 and 17, to determine midazolam and 1-hydroxymidazolam plasma concentrations. 11 blood samples were collected at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours after the administration of oral midazolam, on Days 2, 7 and 18, to determine midazolam and 1-hydroxymidazolam plasma concentrations.

    Time frame: In the turn of 24 hours after IV midazolam, single dose, administered at day 1,6,17 or after oral midazolam, single dose, administered at days 2, 7 and 18.

  8. AUC0-t for Dabigatran (Total and Free), Following Single Doses of the Parent Drug

    AUC0-t =area under the curve from time zero to last sampling time with quantifiable concentrations. AUC0-t of total dabigatran and free dabigatran following Administration of Dabigatran Etexilate Alone (Day 1) and Co-Administration of Dabigatran Etexilate and Givinostat (Day 6 - Potential Inhibitory Effect, and Day 17 - Potential Inducing Effect). Fifteen (15) blood samples were collected at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after the administration of dabigatran etexilate, on Days 1, 6 and 17, for the determination of total and free dabigatran plasma concentrations.

    Time frame: In the turn of 72 hours after administration of dabigatran on day 1,6,17

  9. AUC0-inf of Midazolam, 1-hydroxymidazolam, Following Single Doses of Givinostat

    AUC0-inf=Total AUC extrapolated to infinity, calculated as AUC0-t + Clast/λz, where Clast is the last measurable concentration and λz is the apparent terminal elimination rate constant. 13 blood samples were collected at pre-dose and at 2 minutes, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12 and 24 hours after the administration of IV midazolam, on Days 1, 6 and 17, to determine midazolam and 1-hydroxymidazolam plasma concentrations. 11 blood samples were collected at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours after the administration of oral midazolam, on Days 2, 7 and 18, to determine midazolam and 1-hydroxymidazolam plasma concentrations.

    Time frame: In the turn of 24 hours after IV midazolam, single dose, administered at day 1,6,17 or after oral midazolam, single dose, administered at days 2, 7 and 18.

  10. AUC0-inf for Dabigatran (Total and Free), Following Single Doses of the Parent Drug

    AUC0-inf = Total AUC extrapolated to infinity, calculated as AUC0-t + Clast/λz, where Clast is the last measurable concentration and λz is the apparent terminal elimination rate constant. AUC0-inf of total dabigatran and free dabigatran following Administration of Dabigatran Etexilate Alone (Day 1) and Co-Administration of Dabigatran Etexilate and Givinostat (Day 6 - Potential Inhibitory Effect, and Day 17 - Potential Inducing Effect). Fifteen (15) blood samples were collected at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after the administration of dabigatran etexilate, on Days 1, 6 and 17, for the determination of total and free dabigatran plasma concentrations.

    Time frame: In the turn of 72 hours after administration of dabigatran on day 1,6,17

  11. %AUCextrap of Midazolam, 1-hydroxymidazolam, Following Single Doses of Givinostat

    Area under the curve or AUC is a pharmacokinetic statistic used to describe the total exposure to a drug. More specifically, it is the time-averaged concentration of drug circulating in the body fluid analyzed (normally plasma, blood or serum). Standard calculation of AUC involves using non-compartmental techniques to calculate the AUC from time 0 to the last measurable concentration. This is called AUC0-t and represents the observed exposure to a drug. The total AUC or AUC0-∞ is the area under the curve from time 0 extrapolated to infinite time. %AUCextrap = Percentage of AUC0-∞ due to extrapolation from the time of the last measurable concentration (tlast) to infinity, i.e., residual area, calculated as 100 ∙(AUC0-∞ - AUC0-t) / AUC0-∞.

    Time frame: In the turn of 24 hours after IV midazolam, single dose, administered at day 1,6,17 or after oral midazolam, single dose, administered at days 2, 7 and 18.

  12. %AUC0extrap (%) for Dabigatran (Total and Free), Following Single Doses of the Parent Drug

    Area under the curve (AUC) is a pharmacokinetic statistic used to describe the total exposure to a drug. More specifically, it is the time-averaged concentration of drug circulating in the body fluid analyzed. The total AUC (AUC0-∞) is the area under the curve from time 0 extrapolated to infinite time. * AUC0extrap = Percentage of AUC0-∞ due to extrapolation from the time of the last measurable concentration (tlast) to infinity, i.e., residual area, calculated as 100 ∙(AUC0-∞ - AUC0-t) / AUC0-∞. * AUC0extrap of total dabigatran and free dabigatran following Administration of Dabigatran Etexilate Alone (Day 1) and Co-Administration of Dabigatran Etexilate and Givinostat (Day 6 - Potential Inhibitory Effect, and Day 17 - Potential Inducing Effect). Fifteen (15) blood samples were collected at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after the administration of dabigatran etexilate, on Days 1, 6 and 17, for the determination of total and free dabigatra

    Time frame: In the turn of 72 hours after administration of dabigatran on day 1,6,17

  13. λz of Midazolam, 1-hydroxymidazolam, Following Single Doses of Givinostat

    Apparent first order elimination rate constant associated with the terminal (log-linear) portion of the concentration versus time curve. The parameter is estimated by linear least square regression analysis using the last three (or more) non-zero concentrations. 13 blood samples were collected at pre-dose and at 2 minutes, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12 and 24 hours after the administration of IV midazolam, on Days 1, 6 and 17, to determine midazolam and 1-hydroxymidazolam plasma concentrations. 11 blood samples were collected at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours after the administration of oral midazolam, on Days 2, 7 and 18, to determine midazolam and 1-hydroxymidazolam plasma concentrations.

    Time frame: In the turn of 24 hours after IV midazolam, single dose, administered at day 1,6,17 or after oral midazolam, single dose, administered at days 2, 7 and 18.

  14. λz of Dabigatran (Total and Free), Following Single Doses of Givinostat

    Apparent first order elimination rate constant associated with the terminal (log-linear) portion of the concentration versus time curve. The parameter is estimated by linear least square regression analysis using the last three (or more) non-zero concentrations. Fifteen (15) blood samples were collected at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after the administration of dabigatran etexilate, on Days 1, 6 and 17, for the determination of total and free dabigatran plasma concentrations.

    Time frame: In the turn of 24 hours after IV midazolam, single dose, administered at day 1,6,17 or after oral midazolam, single dose, administered at days 2, 7 and 18.

Secondary outcomes

  1. Number of Adverse Events by Severity (Mild, Moderate, Severe)

    An AE was considered as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily imply a causal relationship with this treatment. An AE can, therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. The period of observation for the collection of medical occurrences extended from the time when the subject gave Informed Consent until the follow-up visit.

    Time frame: Throughout the study and 10-14 days after the EoS (follow-up visit), i.e. up to date 30-34

  2. Incidence of Patients With at Least One Adverse Events by Severity (Mild, Moderate, Severe)

    An AE was considered as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily imply a causal relationship with this treatment. An AE can, therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. The period of observation for the collection of medical occurrences extended from the time when the subject gave Informed Consent until the follow-up visit.

    Time frame: During the study and 10-14 days after the EoS (follow-up visit), i.e. up to day 30-34

07

Results

Posted Jan 6, 2025

Participant flow

Subjects were screened between Days -21 to -3 (both inclusive) of study part 1 to confirm that they met the subject selection criteria. Prior to any screening assessment, the Investigator (or an appropriate delegate) obtained informed consent from each subject in accordance with the procedures. 26 subjects were enrolled to study part 1. Please note that the overall figure n=104 is wrong; the system in fact automatically and inappropriately sums up the number of each IMP group.

Participant flow — Overall Study
MilestoneAll Study Participants (SAF and PK Population)
Started26
Day 1 - midazolam (iv) 1 mg + dabigatran 75 mg26
Day 2 - midazolam (oral) 2.5 mg26
Days 4-5 - givinostat 50 mg b.i.d.26
Day 6 - midazolam (iv) 1 mg + dabigatran 75 mg + givinostat 50 mg b.i.d.26
Day 7 - midazolam (oral) 2.5 mg + givinostat 50 mg b.i.d.26
Days 8-16 - givinostat 50 mg b.i.d.26
Day 17 - midazolam (iv) 1 mg + dabigatran 75 mg + givinostat 50 mg b.i.d.26
Day 18 - midazolam (oral) 2.5 mg + givinostat 50 mg b.i.d.26
Day 19 - givinostat 50 mg26
Completed26
Not completed0

Outcome measures

PrimaryCmax for Midazolam, 1-hydroxymidazolam, Following Single Doses of the Parent Drug

Maximum observed plasma concentration (Cmax) of midazolam and 1-hydroxymidazolam following Administration of Midazolam IV Alone (Day 1) and Co-Administration of Midazolam IV and Givinostat (Day 6 - Potential Inhibitory Effect, and Day 17 - Potential Inducing Effect) and following Administration of Oral Midazolam Alone (Day 2) and Co-Administration of Oral Midazolam and Givinostat (Day 7 - Potential Inhibitory Effect, and Day 18 - Potential Inducing Effect). 13 blood samples were collected at pre-dose and at 2 minutes, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12 and 24 hours after the administration of IV midazolam, on Days 1, 6 and 17, to determine midazolam and 1-hydroxymidazolam plasma concentrations. 11 blood samples were collected at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours after the administration of oral midazolam, on Days 2, 7 and 18, to determine midazolam and 1-hydroxymidazolam plasma concentrations.

Time frame:
In the turn of 24 hours after IV midazolam, single dose, administered at day 1,6,17 or after oral midazolam, single dose, administered at days 2, 7 and 18.
Reported as:
Geometric mean · pg/mL
Cmax for Midazolam, 1-hydroxymidazolam, Following Single Doses of the Parent Drug
pg/mLMidazolam IV Alone (Day 1)Midazolam IV Co-administered With Givinostat (Day 6)Midazolam IV Co-administered With Givinostat (Day 17)Oral Midazolam Alone (Day 2)Oral Midazolam Co-Administered With Givinostat (Day 7)Oral Midazolam Co-Administered With Givinostat (Day 18)
midazolam50482.44 (42802.65 to 59540.16)53345.17 (46868.39 to 60716.97)46510.23 (38309.42 to 56466.57)12695.07 (11193.89 to 14397.57)15744.30 (13936.13 to 17787.09)17678.67 (15782.69 to 19802.43)
1-hydroxymidazolam1426.41 (1269.56 to 1602.64)1306.05 (1146.91 to 1487.26)1335.02 (1115.15 to 1598.25)4451.49 (3756.90 to 5274.51)5229.06 (4445.58 to 6150.63)6303.67 (5046.18 to 7874.53)
Statistical analysis
  • Midazolam IV Alone (Day 1) vs Midazolam IV Co-administered With Givinostat (Day 6) · Ratio of the geometric least square mean: 105.67 · 90% CI 91.72 to 121.74
  • Midazolam IV Alone (Day 1) vs Midazolam IV Co-administered With Givinostat (Day 6) · Ratio of the geometric least square mean: 91.56 · 90% CI 86.16 to 97.31
  • Midazolam IV Alone (Day 1) vs Midazolam IV Co-administered With Givinostat (Day 17) · Ratio of the geometric lsmeans: 92.13 · 90% CI 75.97 to 111.73
  • Midazolam IV Alone (Day 1) vs Midazolam IV Co-administered With Givinostat (Day 17) · Ratio of the geometric lsmeans: 93.59 · 90% CI 83.72 to 104.63
  • Oral Midazolam Alone (Day 2) vs Oral Midazolam Co-Administered With Givinostat (Day 7) · Ratio of the geometric lsmeans: 124.02 · 90% CI 114.38 to 134.47
  • Oral Midazolam Alone (Day 2) vs Oral Midazolam Co-Administered With Givinostat (Day 7) · Ratio of the geometric lsmeans: 117.47 · 90% CI 104.78 to 131.69
  • Oral Midazolam Alone (Day 2) vs Oral Midazolam Co-Administered With Givinostat (Day 18) · Ratio of geometric ls means: 139.28 · 90% CI 128.71 to 150.67
  • Oral Midazolam Alone (Day 2) vs Oral Midazolam Co-Administered With Givinostat (Day 18) · Ratio of geometric ls means: 141.61 · 90% CI 122.36 to 163.88
PrimaryCmax for Dabigatran (Total and Free), Following Single Doses of the Parent Drug

Maximum observed plasma concentration (Cmax) of total dabigatran and free dabigatran following Administration of Dabigatran Etexilate Alone (Day 1) and Co-Administration of Dabigatran Etexilate and Givinostat (Day 6 - Potential Inhibitory Effect, and Day 17 - Potential Inducing Effect). Fifteen (15) blood samples were collected in K2-EDTA collection tubes at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after the administration of dabigatran etexilate, on Days 1, 6 and 17, for the determination of total and free dabigatran plasma concentrations.

Time frame:
In the turn of 72 hours after administration of dabigatran on day 1,6,17
Reported as:
Geometric mean · ng/mL
Cmax for Dabigatran (Total and Free), Following Single Doses of the Parent Drug
ng/mLDabigatran Etexilate Alone (Day 1)Dabigatran Etexilate Co-Administered With Givinostat (Day 6)Dabigatran Etexilate Co-Administered With Givinostat (Day 17)
total dabigatran69.44 (51.90 to 92.92)51.17 (39.62 to 66.08)45.35 (34.87 to 58.99)
free dabigatran60.19 (44.64 to 81.14)44.03 (34.49 to 56.21)37.41 (29.01 to 48.23)
Statistical analysis
  • Dabigatran Etexilate Alone (Day 1) vs Dabigatran Etexilate Co-Administered With Givinostat (Day 6) · Ratio of the geometric lsmeans: 73.68 · 90% CI 60.77 to 89.33
  • Dabigatran Etexilate Alone (Day 1) vs Dabigatran Etexilate Co-Administered With Givinostat (Day 6) · Ratio of the geometric lsmeans: 70.38 · 90% CI 57.94 to 85.50
  • Dabigatran Etexilate Alone (Day 1) vs Dabigatran Etexilate Co-Administered With Givinostat (Day 17) · Ratio of the geometric lsmeans: 65.31 · 90% CI 53.33 to 79.98
  • Dabigatran Etexilate Alone (Day 1) vs Dabigatran Etexilate Co-Administered With Givinostat (Day 17) · Ratio of the geometric lsmeans: 62.18 · 90% CI 50.86 to 75.95
PrimaryTmax for Midazolam, 1-hydroxymidazolam, Following Single Doses of the Parent Drug

tmax =Time of occurrence of Cmax. 13 blood samples were collected at pre-dose and at 2 minutes, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12 and 24 hours after the administration of IV midazolam, on Days 1, 6 and 17, to determine midazolam and 1-hydroxymidazolam plasma concentrations. 11 blood samples were collected at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours after the administration of oral midazolam, on Days 2, 7 and 18, to determine midazolam and 1-hydroxymidazolam plasma concentrations.

Time frame:
In the turn of 24 hours after IV midazolam, single dose, administered at day 1,6,17 or after oral midazolam, single dose, administered at days 2, 7 and 18.
Reported as:
Median · hours
Tmax for Midazolam, 1-hydroxymidazolam, Following Single Doses of the Parent Drug
hoursMidazolam IV Alone (Day 1)Midazolam IV Co-administered With Givinostat (Day 6)Midazolam IV Co-administered With Givinostat (Day 17)Oral Midazolam Alone (Day 2)Oral Midazolam Co-Administered With Givinostat (Day 7)Oral Midazolam Co-Administered With Givinostat (Day 18)
midazolam0.03 (0.03 to 0.03)0.03 (0.03 to 0.03)0.03 (0.03 to 0.25)0.55 (0.50 to 1.50)0.50 (0.50 to 1.50)0.50 (0.50 to 1.02)
1-hydroxymidazolam0.50 (0.25 to 1.00)0.50 (0.25 to 2.00)0.51 (0.25 to 2.00)0.55 (0.50 to 1.50)0.50 (0.50 to 1.50)0.50 (0.50 to 1.02)
PrimaryTmax for Dabigatran (Total and Free), Following Single Doses of the Parent Drug

The time of occurrence of maximum observed concentration (tmax) of total dabigatran and free dabigatran following Administration of Dabigatran Etexilate Alone (Day 1) and Co-Administration of Dabigatran Etexilate and Givinostat (Day 6 - Potential Inhibitory Effect, and Day 17 - Potential Inducing Effect). Fifteen (15) blood samples were collected at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after the administration of dabigatran etexilate, on Days 1, 6 and 17, for the determination of total and free dabigatran plasma concentrations.

Time frame:
In the turn of 72 hours after administration of dabigatran on day 1,6,17
Reported as:
Median · hours
Tmax for Dabigatran (Total and Free), Following Single Doses of the Parent Drug
hoursDabigatran Etexilate Alone (Day 1)Dabigatran Etexilate Co-Administered With Givinostat (Day 6)Dabigatran Etexilate Co-Administered With Givinostat (Day 17)
total dabigatran2.00 (1.50 to 4.00)2.00 (1.00 to 4.02)2.00 (1.00 to 4.00)
free dabigatran2.00 (1.00 to 4.00)2.00 (1.50 to 4.02)2.00 (1.50 to 6.00)
Primaryt1/2 of Midazolam, 1-hydroxymidazolam, Following Single Doses of Givinostat

T1/2 is the Apparent terminal elimination half-life, calculated as ln(2)/λz. t1/2 of midazolam and 1-hydroxymidazolam following Administration of Midazolam IV Alone (Day 1) and Co-Administration of Midazolam IV and Givinostat (Day 6 - Potential Inhibitory Effect, and Day 17 - Potential Inducing Effect) and following Administration of Oral Midazolam Alone (Day 2) and Co-Administration of Oral Midazolam and Givinostat (Day 7 - Potential Inhibitory Effect, and Day 18 - Potential Inducing Effect). 13 blood samples were collected at pre-dose and at 2 minutes, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12 and 24 hours after the administration of IV midazolam, on Days 1, 6 and 17, to determine midazolam and 1-hydroxymidazolam plasma concentrations. 11 blood samples were collected at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours after the administration of oral midazolam, on Days 2, 7 and 18, to determine midazolam and 1-hydroxymidazolam plasma concentrations.

Time frame:
In the turn of 24 hours after IV midazolam, single dose, administered at day 1,6,17 or after oral midazolam, single dose, administered at days 2, 7 and 18.
Reported as:
Mean · hours
t1/2 of Midazolam, 1-hydroxymidazolam, Following Single Doses of Givinostat
hoursMidazolam IV Alone (Day 1)Midazolam IV Co-administered With Givinostat (Day 6)Midazolam IV Co-administered With Givinostat (Day 17)Oral Midazolam Alone (Day 2)Oral Midazolam Co-Administered With Givinostat (Day 7)Oral Midazolam Co-Administered With Givinostat (Day 18)
midazolam5.27 (4.60 to 6.04)5.22 (4.61 to 5.90)6.62 (5.83 to 7.51)5.48 (4.75 to 6.32)5.84 (5.08 to 6.70)6.73 (5.89 to 7.70)
1-hydroxymidazolam4.02 (3.41 to 4.74)5.00 (4.20 to 5.95)5.74 (4.70 to 7.03)4.62 (3.63 to 5.89)6.09 (4.76 to 7.80)6.43 (5.16 to 8.01)
Primaryt1/2 for Dabigatran (Total and Free), Following Single Doses of the Parent Drug

Apparent terminal elimination half-life, calculated as ln(2)/λz. The t1/2 of total dabigatran and free dabigatran following Administration of Dabigatran Etexilate Alone (Day 1) and Co-Administration of Dabigatran Etexilate and Givinostat (Day 6 - Potential Inhibitory Effect, and Day 17 - Potential Inducing Effect). Fifteen (15) blood samples were collected at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after the administration of dabigatran etexilate, on Days 1, 6 and 17, for the determination of total and free dabigatran plasma concentrations.

Time frame:
In the turn of 72 hours after administration of dabigatran on day 1,6,17
Reported as:
Median · hours
t1/2 for Dabigatran (Total and Free), Following Single Doses of the Parent Drug
hoursDabigatran Etexilate Alone (Day 1)Dabigatran Etexilate Co-Administered With Givinostat (Day 6)Dabigatran Etexilate Co-Administered With Givinostat (Day 17)
total dabigatran7.96 (7.52 to 8.42)8.01 (7.21 to 8.90)8.74 (8.17 to 9.36)
free dabigatran7.28 (6.73 to 7.89)7.03 (6.35 to 7.77)8.05 (7.30 to 8.88)
PrimaryAUC0-t of Midazolam, 1-hydroxymidazolam, Following Single Doses of Givinostat

AUC0-t =area under the curve from time zero to last sampling time with quantifiable concentrations. AUC0-t of midazolam and 1-hydroxymidazolam following Administration of Midazolam IV Alone (Day 1) and Co-Administration of Midazolam IV and Givinostat (Day 6 - Potential Inhibitory Effect, and Day 17 - Potential Inducing Effect) and following Oral Midazolam Alone (Day 2) and Co-Administration of Oral Midazolam and Givinostat (Day 7 - Potential Inhibitory Effect, and Day 18 - Potential Inducing Effect). 13 blood samples were collected at pre-dose and at 2 minutes, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12 and 24 hours after the administration of IV midazolam, on Days 1, 6 and 17, to determine midazolam and 1-hydroxymidazolam plasma concentrations. 11 blood samples were collected at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours after the administration of oral midazolam, on Days 2, 7 and 18, to determine midazolam and 1-hydroxymidazolam plasma concentrations.

Time frame:
In the turn of 24 hours after IV midazolam, single dose, administered at day 1,6,17 or after oral midazolam, single dose, administered at days 2, 7 and 18.
Reported as:
Median · pg.h/mL
AUC0-t of Midazolam, 1-hydroxymidazolam, Following Single Doses of Givinostat
pg.h/mLMidazolam IV Alone (Day 1)Midazolam IV Co-administered With Givinostat (Day 6)Midazolam IV Co-administered With Givinostat (Day 17)Oral Midazolam Alone (Day 2)Oral Midazolam Co-Administered With Givinostat (Day 7)Oral Midazolam Co-Administered With Givinostat (Day 18)
Midazolam44094.42 (39998.55 to 48609.70)47333.50 (43297.80 to 51745.35)53692.16 (48609.52 to 59306.23)36483.20 (31064.96 to 42846.48)50134.44 (42444.64 to 59217.42)57559.53 (49279.79 to 67230.40)
1-hydroxymidazolam5050.60 (4441.81 to 5742.83)5362.65 (4757.51 to 6044.76)6210.86 (5374.62 to 7177.22)10871.00 (9475.99 to 12471.38)14264.35 (12357.51 to 16465.42)17208.29 (14624.58 to 20248.46)
Statistical analysis
  • Midazolam IV Alone (Day 1) vs Midazolam IV Co-administered With Givinostat (Day 6) · Ratio of the geometric ls means: 107.35 · 90% CI 103.35 to 111.49
  • Midazolam IV Alone (Day 1) vs Midazolam IV Co-administered With Givinostat (Day 6) · Ratio of the geometric lsmeans: 106.18 · 90% CI 100.84 to 111.80
  • Midazolam IV Alone (Day 1) vs Midazolam IV Co-administered With Givinostat (Day 17) · Ratio of the geometric lsmeans: 121.77 · 90% CI 117.56 to 126.12
  • Midazolam IV Alone (Day 1) vs Midazolam IV Co-administered With Givinostat (Day 17) · Ratio of the geometric lsmeans: 122.97 · 90% CI 115.08 to 131.41
  • Oral Midazolam Alone (Day 2) vs Oral Midazolam Co-Administered With Givinostat (Day 7) · Ratio of the geometric lsmeans: 137.42 · 90% CI 128.09 to 147.43
  • Oral Midazolam Alone (Day 2) vs Oral Midazolam Co-Administered With Givinostat (Day 7) · Ratio of the geometric lsmeans: 131.21 · 90% CI 122.47 to 140.59
  • Oral Midazolam Alone (Day 2) vs Oral Midazolam Co-Administered With Givinostat (Day 18) · Ratio of the geometric lsmeans: 157.77 · 90% CI 147.49 to 168.76
  • Oral Midazolam Alone (Day 2) vs Oral Midazolam Co-Administered With Givinostat (Day 18) · Ratio of the geometric lsmeans: 158.30 · 90% CI 145.23 to 172.54
PrimaryAUC0-t for Dabigatran (Total and Free), Following Single Doses of the Parent Drug

AUC0-t =area under the curve from time zero to last sampling time with quantifiable concentrations. AUC0-t of total dabigatran and free dabigatran following Administration of Dabigatran Etexilate Alone (Day 1) and Co-Administration of Dabigatran Etexilate and Givinostat (Day 6 - Potential Inhibitory Effect, and Day 17 - Potential Inducing Effect). Fifteen (15) blood samples were collected at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after the administration of dabigatran etexilate, on Days 1, 6 and 17, for the determination of total and free dabigatran plasma concentrations.

Time frame:
In the turn of 72 hours after administration of dabigatran on day 1,6,17
Reported as:
Median · ng.h/mL
AUC0-t for Dabigatran (Total and Free), Following Single Doses of the Parent Drug
ng.h/mLDabigatran Etexilate Alone (Day 1)Dabigatran Etexilate Co-Administered With Givinostat (Day 6)Dabigatran Etexilate Co-Administered With Givinostat (Day 17)
total dabigatran552.25 (424.19 to 718.98)386.05 (299.12 to 498.25)386.23 (306.46 to 486.78)
free dabigatran460.16 (341.52 to 620.01)341.01 (268.24 to 433.52)332.71 (268.91 to 411.66)
Statistical analysis
  • Dabigatran Etexilate Alone (Day 1) vs Dabigatran Etexilate Co-Administered With Givinostat (Day 6) · Ratio of the geometric lsmeans: 69.90 · 90% CI 58.43 to 83.64
  • Dabigatran Etexilate Alone (Day 1) vs Dabigatran Etexilate Co-Administered With Givinostat (Day 6) · Ratio of the geometric lsmeans: 71.43 · 90% CI 58.67 to 86.98
  • Dabigatran Etexilate Alone (Day 1) vs Dabigatran Etexilate Co-Administered With Givinostat (Day 17) · Ratio of the geometric lsmeans: 69.94 · 90% CI 58.82 to 83.15
  • Dabigatran Etexilate Alone (Day 1) vs Dabigatran Etexilate Co-Administered With Givinostat (Day 17) · Ratio of the geometric lsmeans: 72.30 · 90% CI 59.92 to 87.25
PrimaryAUC0-inf of Midazolam, 1-hydroxymidazolam, Following Single Doses of Givinostat

AUC0-inf=Total AUC extrapolated to infinity, calculated as AUC0-t + Clast/λz, where Clast is the last measurable concentration and λz is the apparent terminal elimination rate constant. 13 blood samples were collected at pre-dose and at 2 minutes, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12 and 24 hours after the administration of IV midazolam, on Days 1, 6 and 17, to determine midazolam and 1-hydroxymidazolam plasma concentrations. 11 blood samples were collected at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours after the administration of oral midazolam, on Days 2, 7 and 18, to determine midazolam and 1-hydroxymidazolam plasma concentrations.

Time frame:
In the turn of 24 hours after IV midazolam, single dose, administered at day 1,6,17 or after oral midazolam, single dose, administered at days 2, 7 and 18.
Reported as:
Median · pg.h/mL
AUC0-inf of Midazolam, 1-hydroxymidazolam, Following Single Doses of Givinostat
pg.h/mLMidazolam IV Alone (Day 1)Midazolam IV Co-administered With Givinostat (Day 6)Midazolam IV Co-administered With Givinostat (Day 17)Oral Midazolam Alone (Day 2)Oral Midazolam Co-Administered With Givinostat (Day 7)Oral Midazolam Co-Administered With Givinostat (Day 18)
Midazolam46054.19 (41834.50 to 50699.50)49532.66 (45406.00 to 54034.35)57112.86 (51342.91 to 63531.25)39037.54 (33096.57 to 46044.94)53379.48 (45107.58 to 63168.29)62904.03 (52906.81 to 74790.32)
1-Hydroxymidazolam5720.13 (4981.56 to 6568.21)6404.39 (5615.24 to 7304.43)7821.70 (6736.26 to 9082.04)11914.16 (10292.86 to 13790.84)15895.61 (13769.86 to 18349.51)19199.79 (16300.75 to 22614.41)
Statistical analysis
  • Midazolam IV Alone (Day 1) vs Midazolam IV Co-administered With Givinostat (Day 6) · Ratio of the geometric lsmeans: 107.55 · 90% CI 103.35 to 111.49
  • Midazolam IV Alone (Day 1) vs Midazolam IV Co-administered With Givinostat (Day 6) · Ratio of the geometric lsmeans: 112.17 · 90% CI 106.21 to 118.46
  • Midazolam IV Alone (Day 1) vs Midazolam IV Co-administered With Givinostat (Day 17) · Ratio of the geometric lsmeans: 124.01 · 90% CI 119.44 to 128.76
  • Midazolam IV Alone (Day 1) vs Midazolam IV Co-administered With Givinostat (Day 17) · Ratio of the geometric lsmeans: 134.29 · 90% CI 126.15 to 142.96
  • Oral Midazolam Alone (Day 2) vs Oral Midazolam Co-Administered With Givinostat (Day 7) · Ratio of the geometric lsmeans: 138.75 · 90% CI 129.05 to 149.18
  • Oral Midazolam Alone (Day 2) vs Oral Midazolam Co-Administered With Givinostat (Day 7) · Gmr corresponds to the ratio of the geom: 134.18 · 90% CI 124.19 to 144.97
  • Oral Midazolam Alone (Day 2) vs Oral Midazolam Co-Administered With Givinostat (Day 18) · Ratio of the geometric lsmeans: 162.76 · 90% CI 151.13 to 175.28
  • Oral Midazolam Alone (Day 2) vs Oral Midazolam Co-Administered With Givinostat (Day 18) · Ratio of the geometric lsmeans: 161.20 · 90% CI 147.80 to 175.82
PrimaryAUC0-inf for Dabigatran (Total and Free), Following Single Doses of the Parent Drug

AUC0-inf = Total AUC extrapolated to infinity, calculated as AUC0-t + Clast/λz, where Clast is the last measurable concentration and λz is the apparent terminal elimination rate constant. AUC0-inf of total dabigatran and free dabigatran following Administration of Dabigatran Etexilate Alone (Day 1) and Co-Administration of Dabigatran Etexilate and Givinostat (Day 6 - Potential Inhibitory Effect, and Day 17 - Potential Inducing Effect). Fifteen (15) blood samples were collected at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after the administration of dabigatran etexilate, on Days 1, 6 and 17, for the determination of total and free dabigatran plasma concentrations.

Time frame:
In the turn of 72 hours after administration of dabigatran on day 1,6,17
Reported as:
Median · ng.h/mL
AUC0-inf for Dabigatran (Total and Free), Following Single Doses of the Parent Drug
ng.h/mLDabigatran Etexilate Alone (Day 1)Dabigatran Etexilate Co-Administered With Givinostat (Day 6)Dabigatran Etexilate Co-Administered With Givinostat (Day 17)
total dabigatran563.09 (436.43 to 726.51)393.93 (306.01 to 507.11)396.25 (315.23 to 498.10)
free dabigatran467.79 (349.48 to 626.16)347.56 (273.95 to 440.95)347.73 (280.67 to 430.81)
Statistical analysis
  • Dabigatran Etexilate Alone (Day 1) vs Dabigatran Etexilate Co-Administered With Givinostat (Day 6) · Ratio of the geometric lsmeans: 69.96 · 90% CI 58.83 to 83.20
  • Dabigatran Etexilate Alone (Day 1) vs Dabigatran Etexilate Co-Administered With Givinostat (Day 6) · Ratio of the geometric lsmeans: 71.65 · 90% CI 59.08 to 86.88
  • Dabigatran Etexilate Alone (Day 1) vs Dabigatran Etexilate Co-Administered With Givinostat (Day 17) · Ratio of the geometric lsmeans: 70.37 · 90% CI 59.64 to 83.03
  • Dabigatran Etexilate Alone (Day 1) vs Dabigatran Etexilate Co-Administered With Givinostat (Day 17) · Ratio of the geometric lsmeans: 73.45 · 90% CI 60.79 to 88.75
Primary%AUCextrap of Midazolam, 1-hydroxymidazolam, Following Single Doses of Givinostat

Area under the curve or AUC is a pharmacokinetic statistic used to describe the total exposure to a drug. More specifically, it is the time-averaged concentration of drug circulating in the body fluid analyzed (normally plasma, blood or serum). Standard calculation of AUC involves using non-compartmental techniques to calculate the AUC from time 0 to the last measurable concentration. This is called AUC0-t and represents the observed exposure to a drug. The total AUC or AUC0-∞ is the area under the curve from time 0 extrapolated to infinite time. %AUCextrap = Percentage of AUC0-∞ due to extrapolation from the time of the last measurable concentration (tlast) to infinity, i.e., residual area, calculated as 100 ∙(AUC0-∞ - AUC0-t) / AUC0-∞.

Time frame:
In the turn of 24 hours after IV midazolam, single dose, administered at day 1,6,17 or after oral midazolam, single dose, administered at days 2, 7 and 18.
Reported as:
Median · Percentage of AUC0-inf
%AUCextrap of Midazolam, 1-hydroxymidazolam, Following Single Doses of Givinostat
Percentage of AUC0-infMidazolam IV Alone (Day 1)Midazolam IV Co-administered With Givinostat (Day 6)Midazolam IV Co-administered With Givinostat (Day 17)Oral Midazolam Alone (Day 2)Oral Midazolam Co-Administered With Givinostat (Day 7)Oral Midazolam Co-Administered With Givinostat (Day 18)
Midazolam3.87 (3.23 to 4.63)3.96 (3.27 to 4.81)5.12 (4.07 to 6.43)5.02 (4.28 to 5.90)5.33 (4.31 to 6.59)5.79 (4.46 to 7.52)
1-Hydroxymidazolam9.72 (7.55 to 12.52)13.20 (10.09 to 17.27)15.97 (12.14 to 21.02)6.95 (5.18 to 9.33)8.42 (6.62 to 10.70)8.80 (7.42 to 10.44)
Primary%AUC0extrap (%) for Dabigatran (Total and Free), Following Single Doses of the Parent Drug

Area under the curve (AUC) is a pharmacokinetic statistic used to describe the total exposure to a drug. More specifically, it is the time-averaged concentration of drug circulating in the body fluid analyzed. The total AUC (AUC0-∞) is the area under the curve from time 0 extrapolated to infinite time. * AUC0extrap = Percentage of AUC0-∞ due to extrapolation from the time of the last measurable concentration (tlast) to infinity, i.e., residual area, calculated as 100 ∙(AUC0-∞ - AUC0-t) / AUC0-∞. * AUC0extrap of total dabigatran and free dabigatran following Administration of Dabigatran Etexilate Alone (Day 1) and Co-Administration of Dabigatran Etexilate and Givinostat (Day 6 - Potential Inhibitory Effect, and Day 17 - Potential Inducing Effect). Fifteen (15) blood samples were collected at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after the administration of dabigatran etexilate, on Days 1, 6 and 17, for the determination of total and free dabigatra

Time frame:
In the turn of 72 hours after administration of dabigatran on day 1,6,17
Reported as:
Median · Percentage of AUC0-inf
%AUC0extrap (%) for Dabigatran (Total and Free), Following Single Doses of the Parent Drug
Percentage of AUC0-infDabigatran Etexilate Alone (Day 1)Dabigatran Etexilate Co-Administered With Givinostat (Day 6)Dabigatran Etexilate Co-Administered With Givinostat (Day 17)
total dabigatran1.37 (1.04 to 1.80)1.79 (1.50 to 2.15)2.23 (1.84 to 2.70)
free dabigatran1.27 (1.00 to 1.62)1.69 (1.39 to 2.05)2.02 (1.58 to 2.58)
Primaryλz of Midazolam, 1-hydroxymidazolam, Following Single Doses of Givinostat

Apparent first order elimination rate constant associated with the terminal (log-linear) portion of the concentration versus time curve. The parameter is estimated by linear least square regression analysis using the last three (or more) non-zero concentrations. 13 blood samples were collected at pre-dose and at 2 minutes, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12 and 24 hours after the administration of IV midazolam, on Days 1, 6 and 17, to determine midazolam and 1-hydroxymidazolam plasma concentrations. 11 blood samples were collected at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours after the administration of oral midazolam, on Days 2, 7 and 18, to determine midazolam and 1-hydroxymidazolam plasma concentrations.

Time frame:
In the turn of 24 hours after IV midazolam, single dose, administered at day 1,6,17 or after oral midazolam, single dose, administered at days 2, 7 and 18.
Reported as:
Median · 1/h
λz of Midazolam, 1-hydroxymidazolam, Following Single Doses of Givinostat
1/hMidazolam IV Alone (Day 1)Midazolam IV Co-administered With Givinostat (Day 6)Midazolam IV Co-administered With Givinostat (Day 17)Oral Midazolam Alone (Day 2)Oral Midazolam Co-Administered With Givinostat (Day 7)Oral Midazolam Co-Administered With Givinostat (Day 18)
Midazolam0.131 (0.115 to 0.151)0.133 (0.118 to 0.150)0.105 (0.092 to 0.119)0.127 (0.110 to 0.146)0.119 (0.103 to 0.136)0.103 (0.090 to 0.118)
1-Hydroxymidazolam0.172 (0.146 to 0.203)0.139 (0.116 to 0.165)0.121 (0.099 to 0.148)0.150 (0.118 to 0.191)0.114 (0.089 to 0.146)0.108 (0.087 to 0.134)
Primaryλz of Dabigatran (Total and Free), Following Single Doses of Givinostat

Apparent first order elimination rate constant associated with the terminal (log-linear) portion of the concentration versus time curve. The parameter is estimated by linear least square regression analysis using the last three (or more) non-zero concentrations. Fifteen (15) blood samples were collected at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours after the administration of dabigatran etexilate, on Days 1, 6 and 17, for the determination of total and free dabigatran plasma concentrations.

Time frame:
In the turn of 24 hours after IV midazolam, single dose, administered at day 1,6,17 or after oral midazolam, single dose, administered at days 2, 7 and 18.
Reported as:
Median · 1/h
λz of Dabigatran (Total and Free), Following Single Doses of Givinostat
1/hDabigatran Etexilate Alone (Day 1)Dabigatran Etexilate Co-Administered With Givinostat (Day 6)Dabigatran Etexilate Co-Administered With Givinostat (Day 17)
Total Dabigatran0.087 (0.082 to 0.092)0.087 (0.078 to 0.096)0.079 (0.074 to 0.085)
Free dabigatran0.095 (0.088 to 0.103)0.099 (0.089 to 0.109)0.086 (0.078 to 0.095)
SecondaryNumber of Adverse Events by Severity (Mild, Moderate, Severe)

An AE was considered as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily imply a causal relationship with this treatment. An AE can, therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. The period of observation for the collection of medical occurrences extended from the time when the subject gave Informed Consent until the follow-up visit.

Time frame:
Throughout the study and 10-14 days after the EoS (follow-up visit), i.e. up to date 30-34
Reported as:
Number · number of TEAE
Number of Adverse Events by Severity (Mild, Moderate, Severe)
number of TEAEMidazolamDabigatranGivinostatTotal
AE mild severity282574127
AE moderate severity0022
AE severe0000
SecondaryIncidence of Patients With at Least One Adverse Events by Severity (Mild, Moderate, Severe)

An AE was considered as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily imply a causal relationship with this treatment. An AE can, therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. The period of observation for the collection of medical occurrences extended from the time when the subject gave Informed Consent until the follow-up visit.

Time frame:
During the study and 10-14 days after the EoS (follow-up visit), i.e. up to day 30-34
Reported as:
Count of participants · Participants
Incidence of Patients With at Least One Adverse Events by Severity (Mild, Moderate, Severe)
ParticipantsMidazolamDabigatranGivinostatTotal
AE mild severity26262626
AE moderate severity2222

Adverse events

Collected over Throughout the study and 10-14 days after the End of Study (safety follow-up visit), i.e. up to day 30-34, all TEAEs, considered related or not related to IMPs, were collected.. Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Midazolam0/26 (0%)0/26 (0%)26/26 (100%)
Dabigatran0/26 (0%)0/26 (0%)26/26 (100%)
Givinostat0/26 (0%)0/26 (0%)26/26 (100%)
Most frequent other events
Showing 10 of 36
Most frequent other events
EventMidazolamDabigatranGivinostat
ThrombocytopeniaBlood and lymphatic system disorders19/2619/2619/26
SomnolenceNervous system disorders17/2617/2617/26
Dry skinSkin and subcutaneous tissue disorders10/2610/269/26
DyspepsiaGastrointestinal disorders7/267/267/26
Faeces softGastrointestinal disorders5/265/264/26
NauseaGastrointestinal disorders5/265/265/26
Blood creatine phosphokinase increasedInvestigations3/263/263/26
DysgeusiaNervous system disorders3/263/263/26
Eye pruritusEye disorders2/262/262/26
Abdominal discomfortGastrointestinal disorders2/262/262/26

Baseline characteristics

Pharmacokinetic Analysis Population:Twenty-six (26) subjects were enrolled in Part 1 of the study and provided evaluable pharmacokinetic data for at least one IMP, without deviations affecting pharmacokinetic interpretation.

Age, Categorical
Age, Categorical(Participants)Number of Subjects Enrolled
<=18 years0
Between 18 and 65 years26
>=65 years0
Age, Continuous
Age, Continuous(years)Number of Subjects Enrolled
Mean34 ± 8.2
Sex: Female, Male
Sex: Female, Male(Participants)Number of Subjects Enrolled
Female7
Male19
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Number of Subjects Enrolled
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White22
More than one race3
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Number of Subjects Enrolled
Portugal26
08

Study locations

1 site
  • Hospital da Prelada, 3rd Floor & East Wing 4th Floor Rua Sarmento de Beires
    Porto, 153 4250-449, Portugal
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in May 2022, 1 month.

Results were first posted in Jan 2025, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2022
First posted
Aug 8, 2022
StartActual
Mar 21, 2022
Primary completionActual
May 8, 2022
CompletionActual
May 24, 2022
Results first posted
Jan 6, 2025
Last update
Jan 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05492318
Lead sponsor
Italfarmaco
Responsible party
Sponsor
First posted
Aug 8, 2022
Start date
Mar 21, 2022
Primary completion
May 8, 2022
Completion
May 24, 2022
Results posted
Jan 6, 2025
Last update
Jan 6, 2025

Study contacts

Marlene Fonseca, MD
principal investigator · Blueclinical, Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Givinostat · Midazolam

Start the discussion